Related to this topic: Patient+ | UK Guidelines | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Immunoglobulins - Normal and Specific

Human immunoglobulins1,2 can be given by IV or IM injection to confer passive (temporary) immunity. They tend to be large volume injections and should be given by deep IM injection into the thigh or buttock, and in children should be divided and given in different sites. They are derived from plasma of non-UK blood donors (to avoid nCJD) and are safe from hepatitis B and C, HIV and syphilis (and can be tested for CMV and malaria if necessary).

There are 2 types of immunoglobulins:

  • Normal (non-specific) - from unselected donors
  • Hyperimmune (specific) - from selected donors
Side-effects of both types:
  • Malaise, chills, fever
  • Headache, nausea, facial flushing
  • Anaphylaxis (rarely)
Human normal immunoglobulin (HNIG)

This provides antibodies against hepatitis A, rubella, measles and other viruses prevalent in the general population. It is most effective within 3 days of contact (but has some effect up to 6 days); protection is immediate and lasts several weeks. They block the immune response to live vaccines (except yellow fever) for 3 months, and live vaccines should ideally be given at least 3 weeks before or 3 months after an injection of HNIG, although this can be ignored if there is insufficient time, eg for travellers.
HNIG is used for:

  • Hepatitis A contact in immuno-compromised patients, preferably given within 72 hours, together with HAV vaccine (in a different site) because there may be a poor antibody response to the vaccine alone. HAV vaccine protects normal individuals if given within a week of contact.
  • Rubella contact in non-immune pregnant women where termination is unacceptable - it does not prevent infection but reduces symptoms and the risk to the fetus. Give as soon as possible after exposure. Serological follow-up is essential. MMR and anti-D may be given in the postpartum period (separate syringes and into different limbs). Measure rubella antibodies after 8 weeks and vaccinate if necessary.
  • Measles contact, within 72 hours of exposure (some effect if given within 6 days) if:
    • Immuno-compromised
    • Non-immune pregnant women (but no evidence it prevents fetal loss)
    • Infant under 9 months - if mother not immune
    • Infant 6-8 months - if mother immune (because under 6 months the child is protected by maternal antibodies and after 9 months MMR can be given for prophylaxis following exposure to measles).

NB: Mumps contact - neither HNIG nor MMR offer protection
Intravenous human normal immunoglobulins allow large amounts to be given, for broad -spectrum passive protection for premature babies, congenital hypogammaglobulinaemia, immunoglobulin deficiencies, autoimmune disorders, eg thrombocytopenic purpura (where temporary rapid rise in platelets needed, eg pregnancy or pre-operatively). Kawasaki syndrome, following bone-marrow transplantation, children with HIV, Guillain-Barre Syndrome, and myaesthenia gravis (unlicensed use) when it can induce remission in severe relapse.

Human Specific Immunoglobulins
  1. Anti-D (Rh0) immunoglobulin, (see separate article on anti-D) 500 units, can be given at 28 weeks, 34 weeks and at birth to rhesus-negative mothers to block fetal RhD-cells from stimulating antibodies (which could cause haemolytic disease of the newborn in future babies). Anti-D is given within 72 hours of abortion, miscarriage or birth, and after any potentially sensitizing situations, eg amniocentesis, antepartum haemorrhage and abdominal trauma. Anti-D can be safely repeated as many times as needed during one pregnancy.
  2. Hepatitis B immunoglobulin (see separate article on hep B immunisation) is used after needle-stick or sexual exposure and in infants born to infected mothers - preferably within 12 hours and not later than 1 week after exposure. Hepatitis B vaccine should also be given.
    Zoster immune globulin is given to the non-immune exposed to chickenpox or shingles if at risk of severe infection:
    • Immuno-compromised individuals
    • high dose steroids (adult who has received 40mg daily for more than a week in the previous 3 months, or a child who has received a daily dose of 2mg/kg for more than a week, or 1mg/kg for more than a month, in previous 3 months)
    • Non-immune pregnant women (to protect the fetus)
    • Neonates of women who develop chickenpox 7 days before/after delivery.
  3. Rabies immune globulin is indicated for an unimmunized person exposed to a bite from an animal from a high risk country; as much as possible is injected into or around the cleansed wound (after washing with soapy water). Rabies vaccine should also be given.
  4. Tetanus immunoglobulin (together with metronidazole and wound cleansing) is given for tetanus-prone wounds, in the non-immune or those not up-to-date with boosters. Tetanus vaccine should also be given. (IV Immunoglobulins are given for treating tetanus).
  5. Cytomegalovirus immune globulin (on a named-patient basis) for patients receiving immunosuppressive treatment.
Rarer Uses of Immunoglobulins
  • Aplastic anaemia - IV anti-lymphocytic globulin (50% respond)
  • Diphtheria anti-toxin (from horses) for suspected diphtheria - reactions are common.
  • Botulism anti-toxin for suspected botulism - reactions are common.
Availability

Immunoglobulins are available from NHS microbiology laboratories, and in Scotland from the Blood Transfusion Service - they are prepared by Bio Products Limited (BPL), and are issued by the Health Protection Agency.


Document References
  1. The Immunoglobulin Handbook of the Health Protection Agency, June 2004
  2. Department of Health; The Green Book; Immunisation Against Infectious Disease (2006)

Internet and Further Reading
  • 24 hour advice is available from the Health Protection Agency (www.hpa.org.uk.) Central Office in London,Tel 020 7759 2700 / 2701, Fax: 020 7759 2733 Email: webteam@hpa.org.uk
AcknowledgementsEMIS is grateful to Dr Peter Kaye for writing this article. The final copy has passed scrutiny by the independent Mentor GP and Pharmacy reviewing teams. ©EMIS 2007.
DocID: 181
Document Version: 1
DocRef: bgp25016
Last Updated: 6 May 2007
Review Date: 5 May 2008


















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page